4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-011707
PRESIDENT AND CEO sold 12,000 shares at $16.89 ($202,700)
- PRESIDENT AND CEO acquired 12,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kintz Samuel · PRESIDENT AND CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-04-25 | Exercise or conversion : show line 1 in the form 10b5-1 | +12,000 | $1.12 | $13,440 | 12,000 | D |
| 2024-04-25 | Sale : show line 2 in the form 10b5-1 | −12,000 | $16.89 | $202,700 | 0 | D |
| Open-market sales · 12,000 sh · avg $16.89 · $202,700 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-04-25 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −12,000 | 200,841 | D |
Loading xslF345X05/form4-04292024_100422.xml…